Claims for Patent: 10,525,033

Summary for Patent: 10,525,033

Title:	Use of amisulpride as an anti-emetic
Abstract:	Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
Inventor(s):	Gilbert; Julian Clive (Cambridge, GB), Gristwood; Robert William (Cambridge, GB), Cooper; Nicola (Essex, GB), Fox; Gabriel (Cambridge, GB)
Assignee:	Acacia Pharma Limited (Duxford, Cambridge, GB)
Application Number:	16/105,268
Patent Claims:	1. A pharmaceutical composition comprising amisulpride in an amount of 2.5 mg per dose or 5 mg per dose, and a pharmaceutically acceptable carrier. 2. The pharmaceutical composition of claim 1, comprising amisulpride in an amount of 2.5 mg per dose. 3. The pharmaceutical composition of claim 1, comprising amisulpride in an amount of 5 mg per dose. 4. The pharmaceutical composition of claim 1, wherein the amisulpride is (S)-amisulpride. 5. The pharmaceutical composition of claim 1, wherein the amisulpride is in the form of a pharmaceutically acceptable salt. 6. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for intravenous injection, intramuscular injection, or subcutaneous injection. 7. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for intravenous injection. 8. The pharmaceutical composition of claim 7, comprising a citrate buffer. 9. The pharmaceutical composition of claim 8, comprising citric acid monohydrate, trisodium citrate dihydrate, and sodium chloride. 10. The pharmaceutical composition of claim 9, comprising 0.25% w/v amisulpride, citric acid monohydrate, trisodium citrate dihydrate, and sodium chloride, wherein the pH of the pharmaceutical composition is 4-7. 11. The pharmaceutical composition of claim 10, comprising 0.25% w/v amisulpride, 0.935% w/v citric acid monohydrate, 1.632% w/v trisodium citrate dihydrate, and 0.18% w/v sodium chloride. 12. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for oral administration. 13. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for sublingual or intranasal administration. 14. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for topical administration. 15. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for transdermal administration. 16. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for rectal administration. 17. A pharmaceutical composition formulated for intravenous injection comprising amisulpride in an amount of less than 50 mg per dose and a citrate buffer. 18. The pharmaceutical composition of claim 17, comprising amisulpride in an amount of 1 mg to 35 mg per dose. 19. The pharmaceutical composition of claim 17, comprising amisulpride in an amount of 1 mg to 20 mg per dose. 20. The pharmaceutical composition of claim 17, comprising amisulpride in an amount of 2.5 mg to 20 mg per dose. 21. The pharmaceutical composition of claim 17, comprising amisulpride in an amount of 2.5 mg per dose. 22. The pharmaceutical composition of claim 17, comprising amisulpride in an amount of 5 mg per dose. 23. The pharmaceutical composition of claim 17, comprising amisulpride in an amount of 20 mg per dose. 24. The pharmaceutical composition of claim 17, wherein the amisulpride is (S)-amisulpride. 25. The pharmaceutical composition of claim 17, wherein the amisulpride is in the form of a pharmaceutically acceptable salt. 26. The pharmaceutical composition of claim 17, comprising citric acid monohydrate, trisodium citrate dihydrate, and sodium chloride.